As with Tulip Mania, panic selling itself in any investment or commodity can get seriously overdone leading to an equal and opposite reaction.
Allergan common and preferred shares are in triage mode Thursday, as company issues update on Restasis patent mess.
Allergan’s clever maneuver to protect its Restasis patent, involving its sale to the Saint Regis Mohawk tribe, is under attack and killing the stock.
After what appeared to be a selling climax last week, both Allergan common and convertible preferred shares soar. But beleaguered Apple shares refuse to follow.
When it comes to patent protection antics, big-pharma company Allergan takes the cake when it comes to legal patent protection creativity.
Steel sector stocks, including U.S. Steel (X) and Cliffs Industries (CLF), does an abrupt about face as Trump opens jawboning efforts on foreign steel dumping.
Just when we were set to do some cautious nibbling on decently priced stocks, the bears roared back into action Tuesday morning. We continue on defense. Puts, anyone?
Gold reverses, oil, financials recover (a bit). It's probably time to take a few profits in our individual portfolios. Safety first!
2017 bounceback stocks have already been bouncing back. Here are the remaining stocks in our list. Any stragglers TBA.
It’s time to dump those big losing stock positions for tax purposes while researching new 2017 year-end bounceback candidates. Like Apple (AAPL).